Recombinant Human LGALS3BP protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3302



Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human LGALS3BP protein Val19-Ser140 (Accession# Q08380) with a rabbit IgG Fc tag at the C-terminus.
GeneID 3959
Accession Q08380
PredictedSize 39.4 kDa
SDS-PAGE 42-55 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Galectin-3-binding protein (LGALS3BP, also known as 90K or Mac-2 BP) is a secreted glycoprotein which binds galectin-3, galectin-1, beta1 integrins, collagens and fibronectin. It has been implicated in tumor metastatic processes, as well as in other cell adhesion and immune functions. Levels of LGALS3BP have been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV).

References:

1. Koths K, et al.J Biol Chem. 268(19):14245-9 (1993). 2. Ullrich A, et al. J Biol Chem. 269(28):18401-7 (1994). 3. Inohara H, et al. Biochem Biophys Res Commun. 201(3):1366-75 (1994). 4. Calabrese G, et al. Cytogenet Cell Genet. 69(3-4):223-5 (1995). 5. Sasaki T, et al. EMBO J. 17(6):1606-13 (1998). 6. Tinari N, et al. Int J Cancer. 91(2):167-72 (2001).